Method for template-based enzymatic DNA synthesis using phosphoryl guanidine oligonucleotides and reaction mixtures for carrying out the method
11643433 · 2023-05-09
Assignee
Inventors
- Maxim Sergeevich Kupryushkin (Novosibirsk, RU)
- Inna Alekseevna Pyshnaya (Novosibirsk, RU)
- Elena Vladimirovna Dmitrienko (Novosibirsk, RU)
- Dmitry Aleksandrovich Stetsenko (Novosibirsk, RU)
- Maksim Leonidovich Filipenko (Novosibirsk, RU)
- Igor Petrovich Oscorbin (Novosibirsk, RU)
- Grigory Aleksandrovich Stepanov (Berdsk, RU)
- Vladimir Aleksandrovich Richter (Novosibirsk, RU)
- Mikhail Konstantinovich Ivanov (Koltsovo, RU)
- Dmitrii Vladimirovich Pyshnyi (Novosibirsk, RU)
Cpc classification
C07H21/00
CHEMISTRY; METALLURGY
International classification
C07H21/00
CHEMISTRY; METALLURGY
Abstract
The invention relates to the development and optimization of PCR and RT-PCR systems used to detect nucleic acids, including the diagnosis of genetic, viral, and other diseases. The essence of the proposed method is that neutral derivatives of oligonucleotides, namely phosphoryl guanidines containing one or more phosphate groups in which guanidine or substituted guanidine residue is introduced on the phosphorus atom, are used as primers for the template-based amplification, including polymerase chain reaction (PCR) and PCR combined with reverse transcription (RT-PCR). The invention allows to obtain more reliable, specific and selective results in the process of PCR, in particular, to increase the sensitivity of PCR by reducing the yield of by-products of DNA amplification and/or to control the yield of the PCR product, including intentionally suppressing, by using different combinations of the location and number of modified phosphate groups in the oligonucleotide primers.
Claims
1. A method for template-based enzymatic DNA synthesis, wherein a primer containing at least one phosphoryl guanidine group corresponding to the General formula (I): ##STR00001## where, each X and Y is independently selected from nucleoside or oligonucleotide; and each of the substituents R1, R2, R3, and R4 can be hydrogen atom H or C.sub.1-C.sub.5 alkyl, or any two from R1-R4, together to form C.sub.2-C.sub.5 alkanediyl, is used to initiate the reaction.
2. The method for template-based enzymatic DNA synthesis according to claim 1, which method is used for amplification of nucleic acids.
3. The method for template-based enzymatic DNA synthesis according to claim 1, which method is used for carrying out polymerase chain reaction.
4. The method for template-based enzymatic DNA synthesis according to claim 1, which method is used for carrying out allele-specific polymerase chain reaction.
5. The method for template-based enzymatic DNA synthesis according to claim 1, which method is used for reverse transcription.
6. The method for template-based enzymatic DNA synthesis according to claim 1, which method is used in both stages of reverse transcription and subsequent polymerase chain reaction.
7. The method for template-based enzymatic DNA synthesis according to claim 1, which method is used for amplification of nucleic acids by the rolling circle mechanism.
8. A reaction mixture for template-based enzymatic DNA synthesis according to claim 1 further comprising a primer containing at least one internucleotide phosphoryl guanidine group corresponding to the formula (I).
9. A set of reaction mixtures for template-based enzymatic DNA synthesis according to claim 1 further comprising a primer containing at least one internucleotide phosphoryl guanidine group corresponding to the formula (I).
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The claimed invention is illustrated by the following figures:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
DETAILED DESCRIPTION OF THE INVENTION
(17) The use of modified oligonucleotides in enzymatic reactions of template-based synthesis of nucleic acids can be accompanied by various effects that affect the overall yield of the reaction. Most of the known chemical modifications of oligonucleotide primers lead to disruption of the interaction of nucleic acid substrates with enzymes. In this context, completely uncharged derivatives of oligonucleotides were never used as primers, since it was obvious from the literature that their carbohydrate-phosphate backbone will not be recognized by enzymes [9].
(18) The invention describes the possibilities of the use of primers with phosphoryl guanidine moieties in template-based enzymatic DNA synthesis systems. In comparison with analogs, the method for template-based enzymatic DNA synthesis using primers containing phosphoryl guanidine moieties [12-14] combines a number of advantages disclosed in the invention, the combination of which ensures the achievement of the technical result.
(19) The general structure of a phosphoryl guanidine group (Z) containing primer is shown in
(20)
(21) The algorithm for construction of PG-modified primer involves the introduction of at least one phosphoryl guanidine moiety into the oligonucleotide and allows the use of completely uncharged phosphoryl guanidine derivatives of oligonucleotides as primers (
(22) One of the key properties and selection criteria for (any) modified oligonucleotides used as primers is their ability to form a competent primer-template complex to initiate the reaction and the ability to act as a template for the synthesis of the 3′-end region of the complementary strand (when the nucleotide sequence of the initial primer acts as the template). The replacement of negatively charged inter-unit phosphate groups with neutral groups, as well as the change in the volume of substituents on the phosphorus atom, should affect the ability of the oligonucleotide to interact with the DNA and RNA template and be extended by DNA- or RNA-dependent DNA polymerases. The invention contains a description of examples demonstrating the ability of oligonucleotides containing phosphoryl guanidine moieties both to act as primers and to provide properties of the template in the process of extension of the complementary strand. Various applications of template-based DNA synthesis, in particular, DNA amplification in molecular diagnostics, biotechnology and genetic engineering, suggest the use of a wide range of DNA polymerases. It was shown that phosphoryl guanidines act as substrates for a wide range of both mesophilic and thermophilic DNA-dependent DNA polymerases, regardless of the presence of 3′.fwdarw.5′/5′.fwdarw.3′ exonuclease activity under the conditions of thermo-cyclic and isothermal modes (Example 2, 3, 4, 5, 6, 10, 13), as well as RNA-dependent DNA polymerases (Example 11, 12).
(23) The presented invention illustrates the possibility of the use of primers with phosphoryl guanidine moieties at various temperatures (temperature protocols) for polymerase (enzymatic) reactions. The described property of the new class of primers can be used in the development of systems for synthesis and diagnostics based on different protocols for the detection and quantification of nucleic acids.
(24) The use of PG-modified primers for amplification of DNA in the PCR reaction, as well as RNA in the reverse transcription reaction with subsequent PCR, seems to be the most demanded. The results obtained using primers with a pre-selected number and position of phosphoryl guanidine moieties demonstrate increased specificity and sensitivity by reducing the yield of non-specific products of the reaction. A key feature that improves the quality of the results of qualitative and quantitative determination of nucleic acids by PCR and RT-PCR with primers containing phosphoryl guanidine moieties is a decrease in the yield of short non-specific products, often classified as “primer-dimers”. (Example 8, 10, 12). The described property will reduce the level of sensitivity and reliability of the quantification of nucleic acids. Reducing the yield of by-products can also be achieved by combining the use of primers with phosphoryl guanidine moieties with already known solutions aimed at modifying other components of the reaction mixture, for example, “hot start” technologies. When used in PCR, phosphoryl guanidines are able to change the amplification factor. Depending on the location, number and frequency of PG-modified monomers, the amplification efficiency can be comparable to the standard reaction with unmodified primers or can be significantly reduced, up to complete elimination of the amplification. The influence on the amplification efficiency can be due to the participation of modified monomers in two main stages, which are initiation of the polymerization reaction and extension of the complementary strand, when the primer nucleotide sequence acts as a template. When selecting the position and number of modified monomers that allow only a slight (within 10-15%) decrease in the amplification efficiency, the use of primers with phosphoryl guanidine moieties will not require a change in the amplification protocol, in particular PCR and RT-PCR, when switching from standard (unmodified) primers for solving particular problems. In addition, the examples demonstrate the possibility of simultaneous use of PG-modified and standard primers in enzymatic reactions (
(25) Using sequencing by the method of Sanger, it was shown that the presence of phosphoryl guanidine moieties does not cause the formation of mutations due to the interaction of the enzyme with modified monomers. This property provides the applicability of PG-modified primers for solving research and practical problems associated with the amplification of nucleic acids, construction of pre-defined sequences and determination of their primary structure.
(26) The control of the synthesis of the 3′-terminal region of one of the strands, in particular the formation of “sticky” ends, is of interest for solving a number of genetic engineering tasks in the construction of artificial DNA molecules with a given nucleotide sequence. For example, “sticky”-end PCR products can be used in the construction of expression plasmid DNA vectors. The present invention demonstrates the possibility of both obtaining a full-size complementary strand and preventing the synthesis of portion of the 3′-terminal units.
(27) An important parameter in choosing the components of amplification systems is the possibility of carrying out a reaction using various objects as a template, for example, synthetic nucleic acids, plasmid DNAs, total RNA, and genomic DNA of cells and tissues, viral nucleic acids, as well as whole body fluids (for example, blood and blood plasma) that are needed in the diagnosis of human and animal diseases. In the examples illustrating the invention, the successful use of PG-modified primers with different variants of the templates is presented, which provides possibilities of widespread implementation of the obtained technical result.
(28) Often, commercially available ready-to-use reaction mixtures are included in laboratory practice to solve routine tasks; moreover, complex stage-by-stage manipulations are usually carried out using sets of reagents containing the necessary components and instructions for conducting an experiment and achieving a scientific or diagnostic result. For practical purposes, the method for template-based enzymatic DNA synthesis using primers with phosphoryl guanidine moieties can be implemented using ready-to-use reaction mixtures and sets of reagents or reaction mixtures for the detection and amplification of nucleic acids, which are in demand for solving both research and diagnostic tasks. Moreover, the stages of amplification of nucleic acids using phosphoryl guanidine derivatives of oligonucleotides can become a part of more complex protocols and sets of reagents for their implementation, for example, the preparation of DNA libraries for differential analysis of gene expression using high-performance methods. The use of the proposed method can not only improve the result of a specific stage of template-based DNA synthesis, but also, in individual applications, will eliminate some stages, for example, intermediate purification from non-specific by-products.
(29) The invention is illustrated in more detail below by the following examples of specific implementation, which do not limit the scope of the invention. Numerous embodiments of the invention within the scope of the claims of the invention that arise from the examples should be apparent to those skilled in the art based on the description above and the following examples. A person skilled in the art will determine the suitability of a particular group or combination of groups and location in the oligonucleotides used as primers in the template-based DNA synthesis reactions empirically and independently.
Example 1. Description of the Systems Used Below
(30) PG oligonucleotides and unmodified oligodeoxyribonucleotides are shown in
(31) PG oligonucleotides acted as primer oligonucleotides (
(32) Native and PG oligonucleotides (
(33) Mesophilic and thermophilic enzymes with and without 3′.fwdarw.5′/5′.fwdarw.3′ exonuclease activity were used as DNA polymerases: Taq DNA polymerase, T5 phage DNA polymerase, E. coli DNA polymerase I (Klenow fragment), DNA polymerase Pfu, RNA-dependent DNA polymerases (revertases) MMLV and HIV-p66; DNA polymerase phi29.
Example 2. PG Oligonucleotide as a Primer in the Reaction Catalyzed by Thermostable Polymerase in Thermo-Cyclic (1) and Isothermal (2) Modes
(34) (1) To demonstrate the use of PG oligonucleotides as primers (the system is shown in
(35) (2) To demonstrate the use of PG oligonucleotides as primers (the system is shown in
(36) It was seen (
Example 3. PG Oligonucleotide as a Primer in the Reaction Catalyzed by Mesophilic Polymerase
(37) To demonstrate the use of PG oligonucleotides as primers (the system is shown in
(38) It was seen (
Example 4. PG Oligonucleotide as a Template in the Reaction Catalyzed by Thermostable Polymerase
(39) To demonstrate the use of PG oligonucleotides as templates (the system is shown in
(40) It was seen (
Example 5. PG Oligonucleotides as a Template in the Reaction Catalyzed by Mesophilic Polymerase
(41) To demonstrate the use of PG oligonucleotides as templates (the system is shown in
(42) It was found (
Example 6. PCR Efficiency Using PG Oligodeoxyribonucleotides as Primers
(43) Amplification of the eGFP gene fragment was carried out in a reaction buffer containing 50 mM Tris-HC, pH 8.5, 50 mM KCl, 0.2 mM of each deoxynucleoside triphosphate, 2 mM MgCl.sub.2, 0.03 units of activity/μl Taq DNA polymerase.
(44) Amplification mode was 95° C. for 5 min, 47 cycles: 95° C. for 10 seconds, 61° C. for 10 seconds, 72° C. for 10 seconds.
(45) A 10-fold serial dilution of plasmid DNA containing the eGFP gene from 10.sup.−9 g to 10.sup.−17 g was used a template.
(46) The pairs shown in
(47) The amplification efficiency was determined by real-time PCR in the presence of intercalating dye SYBR Green I on a LightCycler 96 instrument (Roche, Switzerland).
(48) The amplification efficiency was compared based on the amplification factor values (k.sub.eff), using the approach of the linearizing coordinates of the dependence C.sub.t (lg C.sub.0) (where C.sub.t is the threshold cycle, C.sub.0 is the initial concentration of the template) implemented in the program LightCycler 96 Software version 1.1.0.1320. The amplification factor values are shown in
Example 7. Determination of the Length of the Growing DNA Strand
(49) The amplification of the eGFP gene fragment was carried out in the reaction buffer as described previously in Example 6.
(50) Amplification mode was 95° C. for 5 min, 28 cycles: 95° C. for 10 seconds, 61° C. for 10 seconds, 72° C. for 10 seconds.
(51) Plasmid DNA containing the eGFP gene in an amount of 10.sup.−10 g per reaction was used as a template.
(52) The pairs (*Q0-Z0), (*Q0-ZH1), (*Q0-ZH2), where * is the fluorescent FAM label, were used as primers. PG oligonucleotide sequences are shown in
(53) Determining the exact length of PCR products using fragment analysis was performed in an automated capillary analyzer. The data presented in
Example 8. Comparison of the Accumulation of Specific and Non-Specific Products of PCR Catalyzed by Taq-DNA Polymerase Using Standard and PG-Modified Oligodeoxyribonucleotides as Primers
(54) The amplification of the eGFP gene fragment was carried out in the reaction buffer as described previously in Example 6.
(55) The amplification mode is described previously in Example 7.
(56) The template used is described previously in Example 6.
(57) Pairs of standard native oligonucleotides (Q0-Z0), modified PG oligonucleotides (QH2-ZH2), standard and modified oligonucleotides (QH2-Z0), and a mixture of three oligonucleotides (Z0-QH2/Q0, the last ones in a ratio of 50/50%) were used as primers (forward-reverse). Oligonucleotide sequences are shown in
(58) The analysis of PCR products was carried out by agarose gel electrophoresis (
(59) It was seen (
(60) The complete absence of non-specific products was achieved using PCR systems with deferred “hot” start on modified PG oligonucleotide primers compared with native primers (
Example 9. Analysis of Mutations in the Growing DNA Strand
(61) The amplification of the eGFP gene fragment was carried out in the reaction buffer as described previously in Example 6.
(62) The amplification mode is described previously in Example 7.
(63) The template used is described previously in Example 6.
(64) The pairs (Q0-Z0), (Q0-ZH1), (QH2-ZH2) were used as primers (forward-reverse). Oligonucleotide sequences are shown in
(65) Upon completion of amplification, the purification of PCR products and sequencing thereof by the method of Sanger according to the standard procedure using fluorescently labeled terminators BigDye 3.1 were carried out. Native oligonucleotide primers Q0 and Z0 were used for sequencing.
(66) It was seen (
Example 10. Use of PG Oligonucleotides as Primers for DNA Polymerases Used in Commercial PCR Systems
(67) Three commercial systems were selected to demonstrate the use of PG oligonucleotides as primers. System I contained DNA polymerase Pfu (Sileks, Russia); system II contained a mixture of polymerases Taq and Pfu for PCR of long fragments (PCR of the “Long Range” type) (Biolabmix, Russia); system III for PCR on whole blood “InBlood PCR kit” (Evrogen, Russia) with polymerase “InBlood” (Evrogen, Russia).
(68) For systems I and II, 1 ng of plasmid DNA containing the eGFP gene was used as a template, amplification was performed in the following mode: preliminary denaturation of 95° C. for 5 min, 32 cycles: 9° C. for 10 seconds, 61° C. for 10 seconds, 72° C. for 10 seconds.
(69) For system III, preparations of human whole blood and blood plasma containing previously added 0.2 ng of plasmid DNA per 1 μl of body fluid in the ratio of 2% (for blood plasma only) were used as a template, 5%, 10%, 20%, and 25% of the total volume of the reaction mixture in 25 μl. Amplification was carried out in the mode of 95° C. for 5 min, 26 cycles: 95° C. for 10 seconds, 61° C. for 10 seconds, 72° C. for 10 seconds.
(70) The primer pairs used were (Q0-Z0), (Q0-ZH2), (QH2-Z0), (QH2-ZH2). Oligonucleotide sequences are shown in
(71) The results of the analysis of the PCR products by agarose gel electrophoresis are presented in
Example 11. PG Oligonucleotides as Primers for RNA-Dependent DNA Polymerases (Revertases)
(72) This example demonstrated the possibility of use of PG oligonucleotides P7-P24 labeled with fluorescein as primers for the detection of hepatitis C virus (HCV) RNA as compared to the native oligonucleotide P0. Oligonucleotide sequences are shown in
(73) Fresh blood serum of HCV-infected donors was used as a starting material for analysis. HCV RNA was isolated using the kit “RealBest” Extraction 100 (Vector-Best, Russia) and introduced into the RT-PCR reaction according to the described procedure using either native oligonucleotide P0 or PG oligonucleotides P7-P21 and revertase (MMLV or HIV-p66) at the reverse transcription stage. The reverse transcription reaction (50 μl) was carried out in a mixture of the following composition: PG oligonucleotides (0.5 μM), MgCl.sub.2 (3 mM), Tris-HCl (50 mM) pH 8.0, (NH.sub.4).sub.2SO.sub.4 (10 mM), KCl (30 mM), 0.01% Tween-20, set of dNTP triphosphates (0.4 mM each), BSA 100 μg/ml, MMLV or HIV-p66 (10 units of activity). The reverse transcription reaction was carried out in at least two duplicates in the following temperature mode: 45° C. for 30 min, 95° C. for 3 min.
(74) Next, the obtained cDNA was used for PCR of the HCV-specific fragment. PCR was carried out in a mixture of the following composition: primers CTCCCGGGAGAGCCATAG and TCCAAGAAAGGACCCGGTC (0.5 μM each), buffer (MgCl.sub.2 (3 mM), Tris-SO.sub.4 (50 mM) pH 8.0, (NH.sub.4).sub.2SO.sub.4 (10 mM), KCl (30 mM), 0.01% Tween-20), Taq DNA polymerase (1 unit of activity), fluorescently labeled hydrolysable probe 5′-ROX-TCTGCGGAACCGGTGAGTACACCG-(BHQ2) (0.25 μM), SYBR Green I (at a dilution of 1/10000) or SYTO-13 (at a dilution of 1/2500). Amplification was carried out in the mode of 50° C. for 2 min, 49 cycles: 94° C. for 10 seconds, 60° C. for 20 seconds, 5° C. for 5 seconds, 95° C. for 1 min. The process of HCV detection using a CFX96 instrument (BioRad, USA) and the RealBest HCV RNA kit was carried out in the real-time mode via two channels: ROX is specific detection of a fluorescently labeled hydrolysable probe and FAM is non-specific detection of dsDNA using SYBR Green I dye (
(75) Comparison of substrate properties of the PG oligonucleotides and the native oligonucleotide as primers was carried out by determining the reaction threshold cycle value Ct (threshold cycle), which is shown in
Example 12. PG Oligonucleotides as Primers for DNA Polymerases in One-Step RT-PCR Systems
(76) In the system for one-step RT-PCR “BioMaster RT-PCR SYBR Blue (2-)” (Biolabmix, Russia) containing MMLV revertase and thermostable DNA-dependent Taq DNA polymerase, primers specific for human U12 snRNA sequence were used.
(77) Native oligonucleotides (U0, V0) and PG oligonucleotides (UH1, VH1, WH1) were used as primers. Oligonucleotide sequences are shown in
(78) RT-PCR was performed on a total RNA preparation of human breast adenocarcinoma cells MCF-7 in a concentration range from 6 ng/μl to 8 pg/μl.
(79) The reverting reaction was carried out at 45° C. for 45 minutes
(80) Amplification mode was 95° C. for 5 min, 48 cycles: 95° C. for 10 seconds, 60° C. for 10 seconds, 72° C. for 10 seconds.
(81) Analysis of RT-PCR products was carried out by thermal denaturation and horizontal gel electrophoresis in a 1.5% gel, followed by visualization of the nucleotide material with ethidium bromide (
(82) It was seen (
Example 13. PG Oligonucleotides as Primers in the Amplification Reaction by the Rolling Circle Mechanism (RCA)
(83) This example demonstrates a comparison of the efficiency of DNA amplification reaction by the rolling circle mechanism (RCA) when using PG oligonucleotides and a native oligonucleotide.
(84) Amplification of DNA plasmid pUC19 (0.2 ng) was carried out in a reaction buffer containing Tris-HCl (50 mM) pH 7.5, MgCl.sub.2 (10 mM), (NH.sub.4).sub.2SO.sub.4 (10 mM), DTT (4 mM), in the presence of set of deoxynucleoside triphosphates (0.2 mM each), BSA (200 ng/μl), intercalating dye SYBR Green I, DNA polymerase phi29 (0.5 units of activity/μl), 1 μm of one of the primers.
(85) Amplification mode was 14 hours at 30° C.
(86) PG oligonucleotides D2 and D3 and native oligonucleotide D0 were used as primers. Oligonucleotide sequences are shown in
(87) The amplification products were analyzed by agarose gel electrophoresis in 0.8% agarose using 200 ng of plasmid pUC19 as a marker (M). The results of the analysis are presented in
(88) The obtained ΔCt value was used to calculate the RCA amplification factor with the assumption that the efficiency of the initial conditions is 1 (
Example 14. Increasing the Selectivity of Mutation Detection Using PG Oligonucleotide as a Primer in Allele-Specific PCR
(89) Amplification of the template was carried out in a buffer containing Tris-HCl (65 mM) pH 8.9; (NH.sub.4).sub.2SO.sub.4 (24 mM); MgSO.sub.4 (3 mM), 0.05% Tween-20, set of deoxynucleoside triphosphates (0.2 mM each), Taq DNA polymerase (0.03 units of activity/μl), fluorescently labeled hydrolysable probe 5′-HEX-CTGTATCGTCAAGGCACTCTTGC-BHQ2-3′ (100 nM).
(90) Amplification mode was 95° C. for 3 min, 50 cycles: 95° C. for 10 seconds, 60° C. for 40 seconds.
(91) 2 ng of human genomic DNA isolated from a histological block with colorectal cancer tissue, with or without the addition of a control plasmid containing mutation c.38G>A (G13D) in the KRAS gene fragment (GACTGAATATAAACTTGTGGTAGTTGGAGCTGGTG(G/A)CGTAGGCAAGA GTGCCTTGACGATACAGCTAATTCAGAATCATTTTGTGGACGAATATG) were used as templates, in an amount of 1.1% relative to the total amount of the KRAS gene fragment in genomic DNA.
(92) Pairs of oligonucleotides (forward+reverse) were used as primers: native oligonucleotides S0+S and S1+S, where S and S0 are native oligonucleotides, S1 is a PG oligonucleotide. Each primer was added to the reaction mixture at a concentration of 300 nM. Primer structure is shown in
(93) The selectivity of mutation detection was determined by real-time PCR using a LightCycler 96 instrument (Roche, Switzerland).
(94) For each pair of primers, the average value of the threshold reaction cycle (Ct) and the difference (ΔCt) between the sample containing 1.1% mutation and the sample without mutation were calculated. It was found that the ΔCt of the pair (S1+S) was 9.27, while (S0+S) was 4.42 (
LIST OF REFERENCES CITED
(95) 1. Saiki R. K., Scharf S., Faloona F., Mullis K. B., Horn G. T., Erlich H. A., Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia//Science.—1985.—V. 230.—P. 1350-1354. 2. Mullis K. B., Faloona F. A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.//Methods Enzymol.—1987.—V. 155.—P. 335-350. 3. Ballantyne K. N., van Oorschot R. A., Mitchell R. J. Locked nucleic acids in PCR primers increase sensitivity and performance//Genomics.—2008.—V. 91.—P. 301-305. 4. Brent C. Satterfield cooperative primers: 2.5 million-fold improvement in the reduction of non-specific amplification//J. Mol. Diagn.—2014.—V. 16.—P. 163-173. 5. Bodepudi V., Schoenbrunner N. J., Will S. Methods and reagents for reducing non-specific amplification//WO 2013091835 A1, 27 Jun. 2013. 6. Schneider U. V., Mikkelsen N. D., Lindqvist A., Okkels L. M., Johnk N., Lisby G. Improved efficiency and robustness in qPCR and multiplex end-point PCR by twisted intercalating nucleic acid modified primers//PLoS One.—2012.—V. 7.—e38451. 7. Wanli Bi. Nucleic acid amplification using a reversibly modified oligonucleotide//U.S. Pat. No. 8,334,099 B2. 18 Dec. 2012. 8. Lebedev A. V., Paul N., Yee J., Timoshchuk V. A., Shum J., Miyagi K., Kellum J., Hogrefe R. I., Zon G. Hot start PCR with heat-activatable primers: a novel approach for improved PCR performance//Nucleic Acids Res.—2008.—V. 36.—e131. 9. Summerton J., Stein D., Huang S. B., Matthews P., Weller D., Partridge M. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems//Antisense Nucleic Acid Drug Dev.—1997.—V. 7.—P. 63-70. 10. Chan H. W.-H., Yang Y.-S., Chen W.-Y. Partially neutral single-stranded oligonucleotide//US 20170015699 A1, January 2017. 11. Robinson P. S., Holme J., Jain N. Polymerase chain reaction detection system using oligonucleotides comprising a phosphorothioate group//WO2013140107 A1, 26 Sep. 2013. 12. Stetsenko D., Kupryushkin M., Pyshnyi D. Modified oligonucleotides and methods for their synthesis//WO 2016028187 A1, publication date 25 Feb. 2016. 13. Kupryushkin M S, Pyshnyi D V, Stetsenko D. A. Phosphoryl guanidines. A new class of nucleic acid analogues//Acta Naturae.—2014.—V. 6.—No. 4.—P. 116-118. 14. Kuznetsov N. A., Kupryushkin M. S., Abramova T. V., Kuznetsova A. A., Miroshnikova A. D., Stetsenko D. A., Pyshnyi D. V, Fedorova O. S. New Oligonucleotide Derivatives as Unreactive Substrate Analogues and Potential Inhibitors of Human Apurinic/Apyrimidinic Endonuclease APE1//Molecular BioSystems.—2016.—V. 12.—N1.—P. 67-75.